Quest Diagnostics (DGX) Cash & Equivalents (2009 - 2026)

Quest Diagnostics has reported Cash & Equivalents for 18 years, with the latest figure at $626.0 million in Q2 2026.

• Quarterly Cash & Equivalents rose 96.24% year-over-year to $626.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $626.0 million (up 96.24% YoY) and the FY2025 annual result came in at $420.0 million, down 23.5% from the prior year.
• Cash & Equivalents climbed to $626.0 million in Q2 2026 per DGX's latest filing, from $393.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $790.0 million in Q2 2022 and troughed at $126.0 million in Q2 2023.
• A 5-year average of $449.1 million and a median of $426.0 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 84.05% in 2023, then soared 434.27% in 2024.
• Over 5 years, Cash & Equivalents stood at $315.0 million in 2022, then soared by 117.78% to $686.0 million in 2023, then retreated by 19.97% to $549.0 million in 2024, then slipped by 23.5% to $420.0 million in 2025, then surged by 49.05% to $626.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $626.0 million, $393.0 million, and $420.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.